Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV.
Gemignani
Franco
F
Marbini
Adriana
A
D003449:Cryoglobulinemia / Q000139:chemically induced / Q000150:complications / Q000276:immunology; D006526:Hepatitis C / Q000150:complications* / Q000276:immunology / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D009498:Neurotoxins / Q000009:adverse effects; D018579:Patient Selection; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000150:complications* / Q000276:immunology; D011092:Polyethylene Glycols / Q000009:adverse effects*; D017410:Practice Guidelines as Topic / Q000592:standards; D011446:Prospective Studies; D011994:Recombinant Proteins; D018570:Risk Assessment; D012307:Risk Factors
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009498:Neurotoxins; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a